AKT activity in MM is associated with poor patient prognosis and resistance to currently available treatment.1, 2 It is therefore a logical strategy to inhibit upstream AKT activators, the primary of which is PI3K. This evidence concerns the gene AKT1 and Miyoshi myopathy.